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Abstract:  
BACKGROUND: Parkinson’s disease is the second most common neurodegenerative 
disorder after Alzheimer disease, however to date, there is no approved treatment that 
stops or slows down disease progression. Over the past decades, neuroimaging studies 
including molecular and magnetic resonance imaging are trying to provide insights into 
the mechanisms underlying Parkinson disease.  
METHODS AND FINDINGS: Literature review. It is now becoming clear that these 
imaging modalities can provide biomarkers that can objectively detect brain changes 
related to Parkinson’s disease and monitor these changes as the disease progresses, 
and these biomarkers are required to establish a breakthrough in neuroprotective or 
disease-modifying therapeutics.  
CONCLUSIONS: Here, we provide a review of recent observations deriving from 
positron emission tomography, single positron emission tomography, magnetic 
resonance imaging studies exploring Parkinson’s disease and other parkinsonian 
disorders.   
Key words: Parkinson’s disease, molecular imaging, magnetic resonance imaging, 
imaging biomarker.  
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1. Introduction 
To date, it is difficult to predict the progression of Parkinson’s disease (PD) and 
ensuing treatment complications that may arise. Currently, there is no treatment that 
stops or slows down disease progression in individuals with PD. It is believed that 
progress towards neuroprotective or disease-modifying therapeutics has been affected, 
in part, by the lack of valid, reliable, and clinical-trial ready biomarkers that can 
objectively detect brain changes related to PD and monitor these changes as the 
disease progresses1,2.  
Modern functional neuroimaging techniques have provided important insights into 
neural correlates underpinning PD pathophysiology, potential compensatory 
mechanisms and treatment-related changes from early to advanced stages of the 
disease. Recent developments in magnetic resonance (MR) as well as molecular 
imaging including positron emission tomography (PET) and single-photon emission 
tomography (SPECT) has allowed researchers to gain new insights into the 
pathophysiology of motor, cognitive and behavioural symptoms in PD and other 
parkinsonian disorders. In particular, PET and SPECT studies have enabled the 
investigation of underlying pathological processes such as neurotransmitter dysfunction, 
changes in blood flow and metabolism, neuroinflammation as well as abnormal protein 
aggregation. MR imaging techniques including diffusion MRI (dMRI) and functional MRI 
(fMRI) allow for the exploration of the reorganization of neural pathways and functional 
disruptions that may be proposed as early biomarkers of PD development and 
progression. This review will discuss recent findings of molecular and MR imaging 
studies aiming to better understand symptom development in PD and other 
parkinsonian disorders as well as attempts to identify biomarkers of disease progression 
and treatment complications.   
 
2. Molecular Imaging of PD 
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2.1. The Role of Receptor imaging  
2.1.1. Dopamine 
The profound dopaminergic dysfunction within the striatum is a critical 
neurotransmitter change in the development of PD. There is ample evidence showing 
that this process is widespread and might begin in the lower brainstem and also 
involving other structures, such as the hypothalamus3.  
The level of the membrane dopamine transporter (DAT) seems to be 
downregulated early in PD4, and DAT imaging studies have revealed correlations with 
the severity of PD motor symptoms5-7.  
Recent investigations8 with 11C-dihydrotetrabenazine (DTBZ), a biomarker of 
dopamine neuron integrity have also assessed the striatal dopamine nerve terminal 
degeneration found in the associative striatum, which is generally associated with 
executive processing. Results showed that patients with mild cognitive impairment had 
severe striatal dopamine depletion in the associative (i.e. cognitive) subdivision. Further, 
the evaluation of cortical D2 receptor availability (with 11C-FLB 457) in these patients 
showed also a reduced D2 receptor binding in the bilateral insula compared to 
cognitively normal patients and controls. Although the prefrontal cortex in general has 
generally been a critical region in studies involving dopamine and cognition, these 
findings suggested that striatal dopamine denervation combined with insular D2 
receptor loss may underlie mild cognitive impairment in PD, particularly a decline in 
executive function8. 
 
Treatment of the dopaminergic system is of course, not only associated with the 
amelioration of motor symptoms but also with the development of motor and non-motor 
complications. Impulse control behaviors (ICBs) represent one of the main non-motor 
complications of PD and the use of dopamine agonists (DAs) is associated with an 
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increased risk of their occurrence. It has been recently demonstrated that chronic 
exposure to treatment with DAs but not levodopa, suppresses the D2R striatal 
dopamine receptor availability, which may impact output signaling to frontal lobes9. By 
using a [11C]-raclopride PET challenge, it has been observed that the amount of 
dopamine release after a reward-related cue exposure is higher in those PD patients 
experiencing ICBs10,11. In response to reward cues, PD patients with single or multiple 
ICBs have similar increased ventral striatal dopamine release compared to PD patients 
without ICBs, but the patients with multiple ICBs are more depressed, and have higher 
rates of impulsive sensation-seeking compared to participants with single ICBs and 
without ICBs12. This suggests the implication of both striatal dopamine and possibly 
non-dopaminergic neurotransmission. 
 [123I]-FP-CIT is a radioligand which binds reversibly to striatal presynaptic DAT 
and is used for SPECT imaging. Pavese and colleagues, recently explored the clinical 
phenotype of PD and the degree of nigrostriatal dysfunction - as measured by 123I-FP-
CIT SPECT - at different ages of onset in recently diagnosed patients with untreated 
PD. The authors found that 123I-FP-CIT binding in the most affected putamen was 
similar across the age subgroups. Conversely, binding in the most affected caudate, the 
least affected putamen, and the least affected caudate was lower in older age 
subgroups compared with younger ones, despite similar disease duration. These 
findings suggest the presence of a more widespread involvement of striatal structures in 
older patients, which could reflect the contribution of the aging process to the 
neurodegenerative process of PD and/or a decrease of compensatory mechanisms in 
older patients13. This age-related variability should be taken into account when using 
imaging as a surrogate biomarker of disease progression in clinical trials of disease-
modifying agent, as a floor effect in older patients could affect the interpretation of the 
results.   
2.1.2. SEROTONIN 
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The serotonergic system is profoundly affected in PD14-18 and PET ligands for the 
pre-synaptic serotonergic transporter (SERT), such as [11C]-DASB, are reliable tools to 
assess in vivo serotonergic terminals19. Previous work has demonstrated that the 
administration of levodopa induces markedly higher striatal synaptic dopamine release 
in PD patients with levodopa-induced dyskinesias (LIDs), which can be ameliorated by 
the oral administration of the serotonin receptor type 1A agonist buspirone, a pre-
synaptic modulator of synaptic release in the serotonergic system, prior to levodopa 
administration15. This might be due to a relative preservation of serotonergic terminals in 
the putamen and globus pallidus of PD patients experiencing LIDs18. A further 
confirmation of this hypothesis comes from a recent study showing that the SERT to 
DAT ratio increases as PD progresses whereupon patients experience LIDs17. Overall 
these findings suggest that as the dopaminergic innervation in the striatum becomes 
critically low, the serotonergic system plays a vital role in the development of LIDs by 
handling synaptic dopamine levels in an unregulated manner. Serotonergic 
mechanisms such as excessive striatal innervation and high serotonin to dopamine 
striatal terminal ratio have also been associated with the development of graft-induced 
dyskinesias in PD patients who underwent striatal transplantation with fetal ventral 
mesencephalic tissue20-22. These findings support the role of serotonergic terminals in 
the aberrant release of striatal dopamine and in promoting the development of 
dyskinesias in PD patients. 
123I-FP-CIT SPECT has also been used to assess clinical correlates of brainstem 
raphe serotonergic dysfunction in early stages of PD. Results showed that the 
serotonergic raphe nuclei complex is already dysfunctional in a subgroup of patients 
with less than 2 years of disease. Additionally, lower 123I-FP-CIT binding values in the 
raphe region, which reflects reduced serotonin transporter availability, was associated 
with more severe scores of persistent resting tremor. In these early stages, however, 
levels of raphe serotonergic function did not appear to be related to the non-motor 
6 
 
This article is protected by copyright. All rights reserved.
symptoms of fatigue, depression and sleep disturbance23. In a two-year follow-up study, 
patients with isolated resting tremor had a significant inverse correlation between raphe 
123I-FP-CIT binding and resting tremor amplitude scores. However, in the entire cohort, 
more severe tremor scores were still correlated with lower raphe/putamen binding 
ratios, indicative of more severe raphe dysfunction compared with nigrostriatal 
dysfunction. Interestingly, resting tremor in patients with lower raphe/putamen binding 
ratios responded poorly to dopamine replacement therapy. Taken together, these 
findings indicate that the occurrence of raphe serotonergic dysfunction is associated 
with more severe resting tremor and poorer response to dopaminergic drugs24. 
However, given the non-selective nature of the ligand (123I-FP-CIT), it is not possible to 
rely entirely on this method to assess serotonergic terminal field integrity in brain 
structures where other monoaminergic neuronal populations predominate23 . 
 
2.1.3. Cholinergic dysfunction  
Cognitive changes in PD may result from multifactorial processes that include 
cellular or network dysfunctions due to regional deposition of proteinopathies, 
neurotransmitter changes due to the involvement of important neuromodulator 
projection systems, neuroinflammation or effects of accelerated aging due to the 
interaction of disease-specific changes and cerebral effects of medical 
comorbidities25,26. A dual-syndrome hypothesis of cognitive impairment in PD has been 
proposed where the concept of mild cognitive impairment and fronto-executive 
dysfunction in particular is mainly driven by dopaminergic dysfunction and manifesting 
as deficits in flexibility, planning, working memory, and reinforcement learning. In 
contrast, conversion to dementia in PD might depend on non-dopaminergic, cholinergic 
and more posterior cortical dysfunctions27. More recent studies emphasize the role of 
disruption in global brain networks underlying the development of cognitive impairment 
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in PD28. Interestingly, brain imaging studies have found early changes in the posterior 
temporal-occipital regions which correlated with visual cognitive changes in PD28.  
The cholinergic system is believed to be one of the major neural mechanisms 
underlying progressive cognitive decline in PD. Therefore, failure of the cholinergic 
system may worsen cognitive deficits and make the severity of the dementia syndrome 
worse. A previous acetylcholinesterase PET study found early regional cortical 
vulnerability of occipital association cortices in PD, especially in Brodmann area 1829. 
These are areas that overlap with the ventral and dorsal visual stream of visual cortical 
projections30, which are important for the processing of shape functions and may 
provide a link to the susceptibility of PD to develop visual illusions and ultimately visual 
hallucinations when dementia emerges. Interestingly, a glucose metabolic PET study 
found that patients with PD with mild cognitive impairment who also had visual 
hallucinations had more severe posterior cortical hypometabolism and higher rate of 
conversion to dementia compared to patients with similar mild cognitive impairment but 
no hallucinations31. 
The cholinergic system plays an important role in widespread and diffuse brain 
networks that sub-serve cognitive functioning32. For example, a muscarinic cholinergic 
receptor [123I]-QNB brain SPECT study in patients with PD dementia (PDD) found co-
occurring receptor reductions in anterior cingulate, basal forebrain, insula, temporal, and 
striatal regions. Higher or stable binding, however, was seen in parieto-occipital and 
frontal regions compared to controls33. Interestingly, the topography of receptor binding 
changes that reflected a beneficial response to cholinesterase inhibitor treatment had 
regional overlap with default mode and frontoparietal brain networks. These 
observations may imply a cholinergic role for the maintenance of these networks33. 
More recent studies illustrate interactive cognitive effects of dopaminergic and 
cholinergic neurotransmitter changes in PD. The so-called 'compensatory' hypothesis 
posits that fronto-parietal cortical cholinergic functions associated with top-down control 
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may be recruited (increased cholinergic activity in cortical circuits) to compensate for 
executive dysfunctions associated with striatal dopaminergic declines in early stage 
disease34. Conversely, combined dopaminergic and cholinergic neurotransmitter system 
losses may aggravate cognitive, especially executive function, deficits and jointly 
increase the risk of conversion to PDD34. For example, Kim et al. showed that cortical 
cholinergic integrity was a stronger predictor of conflict processing in PD patients with 
relatively low caudate dopaminergic function35. These findings imply also a more 
nuanced perspective that diverges from the dual-syndrome hypothesis as the 
cholinergic system may make an important contribution to executive dysfunction in PD. 
Acetylcholine can dynamically switch between different cognitive networks 
processing extrinsic versus intrinsic signals36,37, thereby optimizing cognitive flexibility 
and performance. Recent studies in PD support a cholinergic role in switching function 
between large-scale brain network functions where the cortical cholinergic system is 
involved in top-down cognitive control function38, whereas thalamic cholinergic nerve 
terminals may have an important role in bottom-up saliency processing39. Consequently, 
breakdown of these diverse cholinergic systems may result in attentional and executive 
function deficits and behavioral inflexibility in PD. Cognitive control plays an important 
role in mobility40,41 and the cholinergic system has also been implicated in postural 
instability and gait difficulties, in particular slow gait speed, falls and freezing of gait, in 
PD42-45. A post-mortem study confirmed more severe loss of penduculopontine nucleus 
cholinergic neurons in PD fallers compared to non-fallers46. Pharmacological studies of 
fall reducing effects cholinesterase inhibitors provide supplemental evidence of the 
cholinergic system and mobility in PD47,48. 
Other research groups aim to explore the evidence that alpha-synuclein 
pathology in PD could start in peripheral organs including the gastrointestinal tract 
(GIT).  Pavese and colleagues used 11C-donepezil PET, a marker of 
acetylcholinesterase density in the brain and peripheral organs, to assess 
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parasympathetic innervation in the GIT of patients with early PD. They found that 
compared with controls, PD patients had significantly reduced 11C-donepezil uptake in 
the small intestine, colon, and kidneys, providing further support that parasympathetic 
denervation in these organs is present early in the natural history of PD49. 
2.1.4 Phosphodiesterase 10A, Cannabinoid and Noradrenergic system   
Lesions in nigrostriatal dopaminergic projections in animal models of PD lead to 
increased levels of cyclic adenosine monophosphate (cAMP).  Furthermore, treatment 
with levodopa reduces the high cAMP levels observed in the denervated striatum50. In 
striatal neurons, cAMP catabolism is mediated by phosphodiesterases (PDE) such as 
PDE10A. PDE10A is a regulator of cAMP signaling within the striatum and has been 
studied in animal models of PD. Pharmacological modulations with PDE10A inhibitors 
have been shown to ameliorate the severity of levodopa-induced dyskinesias (LIDs), 
restoring physiological cAMP levels in the cortico-striatal-pallidal pathways51. Recent 
findings have demonstrated that PDE10A levels are reduced in the striatum and globus 
pallidus of PD patients and that these measures can be associated with the severity of 
motor symptoms and LIDs52. In particular, using a selective PDE10A radioligand, i.e. 
(11)C-IMA107, a reduced binding was observed in the caudate, putamen and globus 
pallidus which correlated with severity of Unified Parkinson's Disease Rating Scale part-
III motor scores and Unified Dyskinesia Rating Scale scores. These findings suggest 
that nigrostriatal degeneration affects the expression of PDE10A 52. Type 1 cannabinoid 
receptor (CB1) is a modulator of synaptic transmission and potential therapeutic target 
for LIDs53. Using, a CB1-selective radioligand, i.e. [(18)F] MK-9470, PD patients showed 
an increased of CB1 availability in nigrostriatal, mesolimbic, and mesocortical 
dopaminergic projection areas. However, CB1 availability did not differ significantly in 
patients with and without LIDs, and there was no correlation with LID severity. Thus, 
these observations demonstrated some regional changes in CB1 availability in PD, but 
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did not reveal a role of CB1 in the pathogenesis of LIDs53. Noradrenergic impairment 
may also play an important role in PD complications54,55. Using a noradrenaline 
transporter, 11C-MeNER, PD patients had a reduced binding which correlated with 
amount of REM sleep behavioral disorders (RBDs), cognitive performance, and 
orthostatic hypotension. Thus, impaired noradrenergic function in PD may contribute to 
a number of non-motor symptoms54,55. 
 
2.2. The Contribution of neuro-inflammation and proteinopathies  
The development of radiotracers specifically targeting pathological protein 
aggregates such as tau and β-amyloid, as well as markers of neuroinflammation has 
been a particular focus within the last years.  
The radiotracer [18F]-AV-1451, a ligand that binds to paired helical filaments of 
tau in Alzheimer's disease, has recently been used to explore its potential as a 
biomarker for the diagnosis and disease progression monitoring in progressive 
supranuclear palsy (PSP). Previous findings did not show significant tracer retention in 
PSP patients compared to PD and controls 56, however further investigations with the 
same tracer showed an off-target binding to neuromelanin-containing neurons in the 
midbrain 57,58. These observations demonstrated that [18F]-AV-1451 might be the first 
PET radiotracer capable of imaging neurodegeneration of the substantia nigra in 
parkinsonism. Other tau PET imaging with [11C]PBB3, [18F]THK-5317, [18F]THK-5351, 
showed specific patterns of tau tracer retention in atypical parkinsonism 59-63. These 
observations provide some evidence for the underlying neuropathology, which may in 
future allow tauopathies (e.g. corticobasal degeneration or PSP) to be distinguished 
from non-tauopathies (e.g. multiple-system atrophy [MSA])64. However, the primary 
concern with all these tracers is often the lack of specificity for tau with off target binding 
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(e.g. neuromelanin, monoamine oxidase A/B). Neuroimaging65-69 studies have 
demonstrated as well a relationship between elevated striatal and cortical β- amyloid 
deposits and cognitive impairment in PD65,66. However, in PD with dementia (PDD), the 
distribution of β-amyloid measured with [11C] PIB had a different pattern than those with 
Alzheimer disease69. The presence of an abnormal [11C] PIB binding in PDD under-
estimated at autopsy the risk of β-amyloid-deposition in these people67,68.  
Another area of current interest is the potential usage of the mitochondrial 
translocator protein 18kDa (TSPO) as an in vivo biomarker of neuroinflammation. The 
recent development of second-generation radiotracers such as [18F]-FEPPA enables 
researchers to explore the role of TSPO expression in PD by controlling for genotyping 
expression. While Strafella and colleagues could not observe increased tracer uptake in 
the striatum 70 or in the cortical and subcortical brain regions 71 in patients with PD 
compared to controls, the combination of the radioligands [18F] FEPPA and [11C] PIB, a 
measure of β-amyloid load, revealed interesting findings. The dual-tracer PET study 
detected significantly higher [18F] FEPPA binding in PD patients with cognitive 
impairment in the frontal and temporal lobe, striatum, precuneus and dorsolateral 
prefrontal cortex, when β-amyloid was present in these brain regions72. Other areas of 
research focus on patients with idiopathic Rapid Eye Movement Sleep Behavior 
Disorder (iRBD) who could be in the pre-motor phase of alpha-synucleinopathies such 
as PD, dementia with Lewy bodies (DLB), and MSA. Pavese and colleagues used PET 
imaging to explore the extent and distribution of early inflammation (microglia activation) 
in the brain of iRBD to clarify whether it could contribute to the neurodegenerative 
process of developing alpha-synucleinopathies. The relationship between 
neuroinflammation and striatal and extrastriatal dopamine dysfunction was also 
investigated.  They found that 11C-PK11195 binding, a marker of activated microglia 
was significantly increased in the substantia nigra of iRBD patients compared to 
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controls. Increased binding was also observed at a lesser extent in the putamen and 
caudate nuclei bilaterally. Individual analysis showed that 26% of the iRBD patients had 
significant increases in 11C-PK11195 binding in the putamen and/or caudate (> 2 
standard deviations above the mean of the controls), suggesting that 11C-PK11195 PET 
can be used to identify individual iRBD patients who have high levels of 
neuroinflammation. Activated microglia were also found in the visual associative cortex 
of the occipital lobe of these patients, which might potentially indicate those at greater 
risk of developing DLB. However, 11C-PK11195 is known for its technical limitations 
such as low signal-to-noise ratio, high nonspecific binding, low brain penetration, and 
high plasma protein binding73. Analysis of nigrostriatal function with 18F-dopa PET in 
individual iRBD patients showed that a subgroup of these iRBD patients had a 
homogeneous and more widespread decrease of tracer uptake in the striatal sub-
regions including the caudate, possibly suggesting that these patients are in an early 
stage of DLB or MSA rather than idiopathic PD74,75. 
2.3. Blood flow and metabolism 
The valuable role of 18F-FDG PET in the detection of spatial patterns of metabolic 
dysfunction allowing differentiation between different parkinsonian disorders has 
repeatedly been demonstrated76. Moreover, it has been shown that patterns of 
metabolism detected with FDG-PET may correlate more with the clinical phenotype 
(e.g. motor vs. cognitive impairments) than with a specific underlying pathology77. 
When investigating fatigue in PD by using 18F-FDG-PET, results revealed that 
PD patients with higher levels of fatigue showed anti-correlated metabolic changes in 
cortical regions associated with the salience (i.e., right insular region) and default (i.e., 
bilateral posterior cingulate cortex) networks. These observations propose that fatigue 
in PD might be the expression of metabolic abnormalities and impaired functional 
interactions between brain regions linked to the salience and other neural networks78.  
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As mentioned earlier, increased impulsivity and hypomania are non-motor 
symptoms associated with behavioral addictions (e.g. pathological gambling) that may 
occur with dopamine replacement therapy. Recent studies have shown that metabolic 
patterns associated with impulsivity and hypomania in PD are mostly found within the 
fronto-insular network79-81. This is in line with the view that the insula plays an important 
role in various non-motor disturbances in PD82.  
Metabolic activity has also demonstrated spatially distributed networks of brain 
function. In particular, 18F-FDG-PET has provided a means of quantifying highly specific 
spatial covariance patterns associated with PD motor and cognitive functions 83-85 
 
3. Magnetic resonance imaging in PD 
3.1. Magnetic Resonance Imaging Techniques 
Over the past years, researchers are using as well different MR imaging 
techniques such as dMRI and fMRI to study functional disruptions and the 
reorganization of neural pathways in PD and other movement disorders.  
Using dMRI and a computational bi-tensor model instead of a single-tensor 
model, several studies have uncovered a consistent pattern of elevated free water in the 
substantia nigra of patients with PD that progresses over time. For instance, it was 
shown that free water levels in the posterior substantia nigra were elevated in PD 
relative to healthy controls across separate single- and multi-site cohorts86, and this 
region is consistent with the ventrolateral tier of the substantia nigra where 
dopaminergic cell loss is greatest in PD87,88. Furthermore, free water in posterior 
substantia nigra was also elevated in atypical parkinsonian syndromes, consistent with 
more severe pathology in these disorders as compared to PD89. Most importantly, the 
results of a prospective, single-site longitudinal study revealed that free water in 
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posterior substantia nigra increased over the course of 1 year in PD but not in controls, 
and baseline free water predicted changes in bradykinesia and cognitive scores90.  In a 
recent validation study using the Parkinson Progression Marker Initiative Cohort91, it 
was found that (i) free water level in the posterior substantia nigra increased over 1 year 
in de novo PD but not in controls; (ii) free water kept increasing over 4 years in PD; (iii) 
sex and baseline free water predicted 4-year changes in free water; (iv) free water 
increases over 1 and 2 years were related to worsening on the Hoehn and Yahr scale 
over 4 years; and (v) the 4-year increase in free water was associated with the 4-year 
decrease in striatal binding ratio in the putamen. Importantly, all longitudinal results 
were consistent across sites.   
In addition to studies of dMRI, task-based fMRI studies have also revealed 
progression changes in the putamen and motor cortex in parkinsonism.  To explore 
longitudinal changes in brain activity in patients with PD, MSA, and PSP a robust task-
based fMRI protocol was used that has consistently shown cross-sectional changes in 
PD, MSA, and PSP92-94. A total of 112 individuals were scanned 1 year apart while 
performing a unimanual grip force task: 46 PD, 13 MSA, 19 PSP, and 34 controls95. 
Compared with the control group, patients with PD showed a decline in functional 
activity over the course of 1 year in the putamen and motor cortex compared to controls. 
Changes after 1 year in MSA were exclusively extrastriatal, and included a reduction in 
functional activity in the primary motor cortex (M1), supplementary motor area (SMA), 
and superior cerebellum. In PSP, all regions of interest across putamen, cerebellum, 
and motor cortex were less active at 1 year compared to baseline. A key finding was 
that the functional activity of these regions did not change in the control group.   
Latest investigations from Strafella and colleagues96 using fMRI, explored the 
dynamic functional connectivity in PD, focusing on temporal properties of functional 
connectivity states, and the variability of network topological organization. Results 
revealed changes within- as well as between network states in PD versus controls, 
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confirming the vulnerability of functional connectivity networks in this movement 
disorder. 
Recent fMRI work from Lewis and colleagues focuses on the investigation of the 
common clinical phenomena of freezing of gait (FOG) and hallucinations in PD.  
Freezing of gait is a complex, heterogeneous, and highly variable phenomenon 
whose pathophysiology and neural signature remains enigmatic. Evidence suggests 
that freezing is associated with impairments across cognitive, motor and affective 
domains; however, most research to date has focused on investigating one axis of 
freezing of gait in isolation. By contrast, recent work using an established virtual reality 
gait paradigm to elicit freezing behaviour has examined individual differences in the 
differential component processes that underlie freezing of gait (i.e. cognitive, motor and 
affective function)97.  Simultaneously probing three freezing triggers: set-shifting ability 
for cognition, step time variability for motor function, and self-reported anxiety measures 
in a principal components analysis, has allowed a multivariate approach to interrogate 
the pattern of task-based functional connectivity associated with the freezing 
phenomena. Specifically, the investigators used the first principal component from their 
behavioral analysis to classify patterns of functional connectivity into those that were 
associated with: (i) increased severity; (ii) increased compensation; or (iii) those that 
were independent of freezing severity. Coupling between the cognitive and limbic 
networks was associated with ‘worse freezing severity’, whereas anti-coupling between 
the putamen and the cognitive and limbic networks was related to ‘increased 
compensation’. Additionally, anti-coupling between cognitive cortical regions and the 
caudate nucleus were ‘independent of freezing severity’ and thus may represent 
common neural underpinnings of freezing that are unaffected by heterogenous factors.  
Subsequently, these investigators related these connectivity patterns to each of the 
individual components of freezing in turn (i.e. cognitive, motor, affective), thus exposing 
latent heterogeneity in the freezing phenotype whilst also identifying critical functional 
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network signatures that may represent potential targets for novel therapeutic 
intervention. In conclusion, the findings from this study provided confirmatory evidence 
for systems-level impairments in the pathophysiology of freezing of gait and further 
advances our understanding of the whole-brain deficits that mediate symptom 
expression in PD. 
Visual hallucinations are a common and troubling neuropsychiatric feature in 
more advanced PD but the ability to capture such activity using fMRI has been severely 
restricted98.  However, the recent development of a neuropsychological paradigm that 
can reliably induce visual misperceptions in PD patients reporting visual hallucinations99 
has allowed for its combination with fMRI to provide greater insights into the 
pathophysiology of this phenomenon100,101. This work has demonstrated that visual 
hallucinations seem to arise from an increased engagement of the Default Mode 
Network (DMN) (operating across the hippocampal formations, posterior cingulate and 
intraparietal sulcus) with the primary visual system.  This is the result of a disengaged 
Dorsal Attention Network (representing regions of the frontal eye fields and superior 
parietal lobule), which would normally maintain directed attention and prevent 
hallucinations arising.  These fresh clues may provide the basis of future treatments 
targeting pathological network activity102. 
Resting-state functional magnetic resonance imaging (RS-fMRI) is a relatively 
new, non-invasive tool to assess functional abnormalities observed in PD without the 
effects of motor or cognitive tasks. A recent meta-analysis of RS-fMRI studies in PD 
found evidence for an intrinsic functional disturbance of the inferior parietal lobule (IPL) 
and the supra-marginal gyrus potentially linked to functional impairment of perception 
and executive processes103. However, when interpreting RS-fMRI results, it is important 
to consider the impact of dopamine replacement therapy104.  
Tessitore and colleagues applied RS-fMRI to study functional disruption and 
reorganization of neural pathways that may be proposed as early biomarkers of PD 
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development and progression. Among the most reported RS networks, alterations within 
the sensori-motor network (SMN) have been consistently reported across PD stages by 
means of different analytic approaches105,106. In a cohort of drug-naïve early PD 
patients, the authors have demonstrated the presence of functional connectivity 
disruption in the SMA compared to controls, partially restored by the first levodopa 
administration compared to placebo107. Moreover, a region of interest analysis of the 
SMN functional connectivity within the basal ganglia revealed that levodopa significantly 
increased the participation of these subcortical regions to the SMN activity and may 
selectively induces low-frequency rhythm changes107. Interestingly, SMN connectivity 
abnormalities were also detected in asymptomatic LRRK2 (G2019S) mutation carriers, 
suggesting that functional changes may also occur earlier during the preclinical phase 
of the disease108,109. 
As SMN functional connectivity has consistently shown a levodopa modulation 
and symptoms severity correlation, the authors could speculate that: 1) SMN functional 
connectivity disruption may be considered as a neural correlate of the cortico-striatal 
disruption which underlies PD pathophysiology, even before symptoms emerge, 2) SMN 
connectivity may be potentially used as a biomarker of both symptom development and 
treatment response throughout the disease course. 
In recent years, an intrinsic aberrant functional connectivity within the DMN has 
been implicated in cognitive processing in several neurodegenerative disorders110-112, 
including PD113-115, with and without cognitive impairment116,117.  In a cohort of early-
stage cognitively unimpaired patients with PD, researchers demonstrated the presence 
of decreased medial temporal and inferior parietal connectivity within the DMN, which 
correlated with cognitive performance116. This finding suggests that functional 
disconnection of posterior brain regions can precede clinically measurable cognitive 
impairment in PD118 and may be proposed to develop a sensitive and specific biomarker 
of dementia in PD for prognostic and disease-monitoring purposes. 
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Together with the DMN, other so-called neurocognitive networks, such as the 
salience (SN) and the central-executive (CEN) networks, have been implicated into PD 
progression. Typically, the SN and CEN show increased activation in response to 
external stimuli119, whereas DMN activity is suppressed, resulting in anti-correlated 
coupling between the CEN and DMN120,121. The same pattern of interaction among the 
three neurocognitive networks has been also shown at rest122,123. This dynamic balance 
may allow an individual to remain prepared for unexpected environmental events120 and 
seems to be critical in generating and maintaining an efficient behavioral and cognitive 
performance122. Interestingly, using RS-fMRI Tessitore and colleagues highlighted the 
presence of a disrupted connectivity within these three networks in treated PD patients 
with ICBs compared to those without124. These behavioral symptoms may be triggered 
by dopamine replacement treatment in a specific subset of patients, showing clinical risk 
factors which are not able, to date, to predict their development. To fill this gap, the 
researchers investigated the intrinsic brain networks connectivity at baseline in a cohort 
of drug-naïve PD patients that subsequently developed ICB (ICB+) over a 36-month 
follow-up period compared with patients who did not (ICB-)125. The imaging data 
demonstrated the presence of a specific decreased connectivity within and between the 
DMN and CEN networks at baseline as well as an increased connectivity within the SN 
in ICB+ compared with ICB- patients.  Specifically, the authors found that the 
physiological anti-correlation between DMN/CEN is lost at the time of diagnosis in PD 
patients who are more prone to develop ICB and this inverse pattern seems to predict 
ICB emergence over time. Moreover, this altered DMN/CEN coupling showed a positive 
correlation with the time to ICB onset (i.e. the less the anti-correlation between DMN 
and CEN the earlier is the emergence of ICB). These connectivity changes are 
independent from motor, behavioral and cognitive features and do not result from 
chronic dopaminergic treatment, suggesting that it may represent a potential biomarker 
for the emergence of ICB symptoms. 
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Further investigations have aimed to explore functional changes in sensorimotor 
and cognitive networks in PD, focusing on inter- and intra-connectivity organization in 
the disease-associated nodal and hub regions using graph theoretical analyses. To 
date, findings have highlighted diffuse alterations in nodal organization and regional hub 
disruption that result in a number of distributed abnormalities across brain networks that 
may be related to the specific clinical manifestations of PD126. 
3.2. The role of Ultra-High Field (UHF) Imaging 
Despite several limitations, MR imaging has certainly enhanced the diagnostic 
accuracy in the differential diagnosis of neurodegenerative parkinsonism over the last 
years. 
Technological advances and the introduction of high-field 3 Tesla (3T) and ultra-
high-field 7 Tesla (7T) MRI have led to improved spatial resolution and contrast thus 
enabling better visualization of brain structures affected in neurodegenerative disorders. 
Consequently, a new MRI finding has been described in the substantia nigra on iron-
sensitive MRI sequences capable of differentiating between PD patients and controls127. 
In controls, a hyperintense ovoid area within the dorsolateral border of the otherwise 
hypointense substantia nigra pars compacta (SNpc), referred to as dorsolateral nigral 
hyperintensity (DNH), has been recognized. DNH seems to correspond 
histopathologically to nigrosome-1, a calbindin-negative subregion in the SNpc127. A 
recent meta-analysis128 evaluated DNH as an imaging marker for PD, concluding that 
visual assessment of DNH could provide excellent diagnostic accuracy for PD 
compared to controls. The loss of DNH may enable the discrimination between PD and 
other movement disorders including drug-induced parkinsonism, essential tremor, and 
dystonic tremor128. Studies in iRBD cohorts129 have shown that at least two third of 
these patients had a loss of DNH as seen in PD. Therefore, loss of DNH could 
represent a potential marker for prediagnostic stages of PD128.  
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4. Future Directions & Conclusions 
Overall, previous and current work has provided some insights on PD and 
parkinsonian disorders and their underlying pathophysiological abnormalities. These 
observations have offered researchers and clinicians a better understanding of the 
neural correlates of the symptoms experienced in PD such as cognitive dysfunction, 
FOG and hallucinations as well as subsequent treatment complications including ICBs. 
Nonetheless, the visualization of neuroanatomical and functional hallmarks of these 
pathological conditions remains an active and challenging area, while PET and MR 
imaging have raised their value as powerful tools to detect brain changes. These 
neuroimaging techniques have also proven to be helpful in the clinical setting e.g. 
metabolic PET and structural or dMRI can accurately distinguish PD from atypical 
parkinsonism. Further, dopaminergic and serotonergic PET and SPECT imaging can 
follow the development of motor and nonmotor symptoms and complications as the 
disease progresses whereas metabolic, cholinergic and β-amyloid PET methods are 
useful for investigating cognitive decline in PD130.  
There are several factors delaying the transfer of neuroimaging techniques from 
the research setting into clinical practice. For instance, many research achievements 
have derived from PET imaging, which is a powerful tool, however also expensive and 
not widely available. Most biomarkers are unsuitable for individual level type of analysis, 
and allow only group-wise comparison. Moreover, several PET and MRI techniques 
depend on sophisticated quantification, which necessitates specialized software and 
skilled technicians. Another prerequisite for clinical application is standardized data 
processing and the availability of well-defined imaging criteria. The combination of PET 
and MR imaging may be helpful in determining diagnostic criteria based on these 
innovative MRI techniques. Also, data from different investigational modalities need to 
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be united to recognize mechanisms that are meaningful drug targets. Lastly, physicians 
require training and experience with these techniques to obtain optimization130.  
 
PD remains a complex neurodegenerative disease, and several novel 
neuroimaging techniques require further research and longitudinal assessments to 
evaluate their stability and validity as PD biomarkers before being recommended for 
routine clinical practice130. 
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